[Thrombelastographic studies made to objectify the effects of Grisaldon upon the process of coagulation (author's transl)].
Thrombelastographic studies of the mode of action of Grisaldon showed that this preparation, unlike the pure substance of acetylsalicylic acid, has no appreciable coagulation-accelerating and fibrin-stabilizing effects. In addition, it was possible to show that an antifibrinolytic effect of the p-oxybenzoic acid propyl ester (Grisaldon component), which has been described in the literature, is not produced.
D001241:Aspirin / Q000627:therapeutic use*; D001777:Blood Coagulation / Q000187:drug effects*; D004338:Drug Combinations; D004341:Drug Evaluation; D006801:Humans; D066298:In Vitro Techniques; D010226:Parabens / Q000627:therapeutic use; D011208:Powders; D013916:Thrombelastography; D014914:Whole Blood Coagulation Time
D004338:Drug Combinations; D010226:Parabens; D011208:Powders; D001241:Aspirin
Thrombelastographische Untersuchungen zur Objektivierung der Einwirkung von Grisaldon auf den Gerinnugsprozess.